";s:4:"text";s:4468:"Folgen Sie den Anweisungen auf dem Beipackzettel. Tofacitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tofacitinib. Sirolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus. Use in CYP2D6 EMs who are also taking strong or moderate CYP2D6 inhibitors is contraindicated. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. For these reasons, before you start taking dapoxetine it is important that your doctor knows:Along with their useful effects, most medicines can cause unwanted side-effects although not everyone experiences them. Not compatible with polyurethane-containing IV administration sets; refer to manufacturer's labeling for compatible infusion sets.Injection: Store intact vials at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Management: Avoid use of pexidartinib with moderate CYP3A4 inhibitors if possible. Excipient information presented when available (limited, particularly for generics); consult specific product labeling.Prevymis: 240 mg/12 mL (12 mL); 480 mg/24 mL (24 mL)Letermovir inhibits cytomegalovirus (CMV) replication by targeting the CMV DNA terminase complex (pUL51, pUL56, pUL89), which is required for viral DNA processing and packaging. Entsorgen Sie jeden Rest des Medikaments nach Ablauf des Verfalldatums. Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. €134.87 Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant. Infuse via a 0.2- or 0.22-micron polyethersulfone in-line filter. Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. Management: Avoid concomitant use of OATP1B1/1B3 substrates in patients receiving the Jynarque brand of tolvaptant. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.